TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy firm, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on September 29 at 2:00PM E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy firm, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on September 29 at 2:00PM E.T. This event allows investors to gain insights into the company's innovative T cell therapies targeting solid tumors. A live webcast will be available on the company's Investors page, and a replay will be accessible for 30 days post-event.
TCR2 develops proprietary TRuC®-T cells designed to target cancer cells effectively.
Details
News Market Reaction – TCRR
The recorded move for TCRR in the trading session of this news was -2.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.
A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit www.tcr2.com.
Investor and Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.